Ambry Genetics, a leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., today announced the ExomeReveal™ test, a new multiomic exome sequencing test designed to improve rare disease ...

In a recent article published in BMC Medical Genomics, researchers recruited a cohort of 25 Chinese genodermatoses patients to examine the genetic etiology by whole-exome sequencing (WES). They ...

A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...

A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

There are more than 7,000 rare disorders, and many cannot be diagnosed in a doctor’s office. That’s why genetic sequencing is so important. Now The Jackson Laboratory in Farmington is able to sequence ...

GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...